Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer

NCT00019474 is registered in ClinicalTrials.gov with Montefiore Medical Center as lead sponsor.

NCT NCT00019474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00019474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer
Lead sponsor
Montefiore Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1998
Completion date
August 31, 2000
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extrahepatic bile duct cancer, gastric cancer, gastrointestinal carcinoid tumor, liver cancer, pancreatic cancer, small intestine cancer